+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Uveitis - Pipeline Review, H2 2019

  • ID: 4861723
  • Drug Pipelines
  • November 2019
  • Region: Global
  • 248 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 4

FEATURED COMPANIES

  • Aciont Inc
  • Bristol-Myers Squibb Co
  • EnhanX Biopharm Inc
  • HanAll Biopharma Co Ltd
  • NeuClone Pty Ltd
  • OSE Immunotherapeutics
  • MORE
Uveitis - Pipeline Review, H2 2019

Summary

The Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Uveitis - Pipeline Review, H2 2019, provides an overview of the Uveitis (Ophthalmology) pipeline landscape.

Uveitis is swelling and irritation of the uvea, the middle layer of the eye. Uveitis can affect one or both eyes. Uveitis can be caused by autoimmune disorders such as rheumatoid arthritis or ankylosing spondylitis, infection, or exposure to toxins. Symptoms include blurred vision, dark, floating spots in the vision, eye pain, redness of the eye and sensitivity to light. The predisposing factors include having an infection, an autoimmune or inflammatory disorder and history of eye injury. Treatment includes steroid eye drops, anti-inflammatory and antibiotic or antiviral medication.

Report Highlights

The Publisher's Pharmaceutical and Healthcare latest pipeline guide Uveitis - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Uveitis (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Uveitis (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Uveitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical and Discovery stages are 1, 1, 3, 9, 7, 1, 1, 34 and 3 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 3 molecules, respectively.

Uveitis (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from The Publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Uveitis (Ophthalmology).
  • The pipeline guide reviews pipeline therapeutics for Uveitis (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Uveitis (Ophthalmology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Uveitis (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Uveitis (Ophthalmology)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Uveitis (Ophthalmology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Uveitis (Ophthalmology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Aciont Inc
  • Bristol-Myers Squibb Co
  • EnhanX Biopharm Inc
  • HanAll Biopharma Co Ltd
  • NeuClone Pty Ltd
  • OSE Immunotherapeutics
  • MORE
Introduction
Uveitis - Overview
Uveitis - Therapeutics Development
Uveitis - Therapeutics Assessment
Uveitis - Companies Involved in Therapeutics Development
Uveitis - Drug Profiles
Uveitis - Dormant Projects
Uveitis - Discontinued Products
Uveitis - Product Development Milestones
Appendix

List of Tables
Number of Products under Development for Uveitis, H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..2), H2 2019
Number of Products under Development by Universities/Institutes, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Products under Development by Companies, H2 2019 (Contd..2), H2 2019
Products under Development by Companies, H2 2019 (Contd..3), H2 2019
Products under Development by Universities/Institutes, H2 2019
Number of Products by Stage and Target, H2 2019
Number of Products by Stage and Target, H2 2019 (Contd..1), H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..1), H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Uveitis - Pipeline by Aciont Inc, H2 2019
Uveitis - Pipeline by Akari Therapeutics Plc, H2 2019
Uveitis - Pipeline by Aldeyra Therapeutics Inc, H2 2019
Uveitis - Pipeline by Alvotech ehf, H2 2019
Uveitis - Pipeline by Apidel SA, H2 2019
Uveitis - Pipeline by Apitope International NV, H2 2019
Uveitis - Pipeline by Bonac Corp, H2 2019
Uveitis - Pipeline by Bristol-Myers Squibb Co, H2 2019
Uveitis - Pipeline by Chugai Pharmaceutical Co Ltd, H2 2019
Uveitis - Pipeline by Dobecure SL, H2 2019
Uveitis - Pipeline by E&B Technologies LLC, H2 2019
Uveitis - Pipeline by Elasmogen Ltd, H2 2019
Uveitis - Pipeline by Eleusis Ltd, H2 2019
Uveitis - Pipeline by Eli Lilly and Co, H2 2019
Uveitis - Pipeline by Emerald Bioscience Inc, H2 2019
Uveitis - Pipeline by EnhanX Biopharm Inc, H2 2019
Uveitis - Pipeline by Enzo Biochem Inc, H2 2019
Uveitis - Pipeline by EyePoint Pharmaceuticals Inc, H2 2019
Uveitis - Pipeline by Eyevensys SAS, H2 2019
Uveitis - Pipeline by EyGen Ltd, H2 2019
Uveitis - Pipeline by F. Hoffmann-La Roche Ltd, H2 2019
Uveitis - Pipeline by Galapagos NV, H2 2019
Uveitis - Pipeline by HanAll Biopharma Co Ltd, H2 2019
Uveitis - Pipeline by HanAll Biopharma Co Ltd, H2 2019
Uveitis - Pipeline by Idogen AB, H2 2019
Uveitis - Pipeline by InSight Biopharmaceuticals Ltd, H2 2019
Uveitis - Pipeline by IVERIC bio Inc, H2 2019
Uveitis - Pipeline by Kodiak Sciences Inc, H2 2019
Uveitis - Pipeline by Kv1.3 Therapeutics, H2 2019
Uveitis - Pipeline by MetrioPharm AG, H2 2019
Uveitis - Pipeline by Mitotech SA, H2 2019
Uveitis - Pipeline by Naegis Pharmaceuticals Inc, H2 2019
Uveitis - Pipeline by NeuClone Pty Ltd, H2 2019
Uveitis - Pipeline by Novaliq GmbH, H2 2019
Uveitis - Pipeline by Novartis AG, H2 2019
Uveitis - Pipeline by Oculis SA, H2 2019
Uveitis - Pipeline by OKYO Pharma Ltd, H2 2019
Uveitis - Pipeline by OncoNOx ApS, H2 2019
Uveitis - Pipeline by Orchid Pharma Ltd, H2 2019
Uveitis - Pipeline by OSE Immunotherapeutics, H2 2019
Uveitis - Pipeline by Palatin Technologies Inc, H2 2019
Uveitis - Pipeline by Panag Pharma Inc, H2 2019
Uveitis - Pipeline by Panoptes Pharma GesmbH, H2 2019
Uveitis - Pipeline by Pfizer Inc, H2 2019
Uveitis - Pipeline by Pharmapraxis, H2 2019
Uveitis - Pipeline by Re-Pharm Ltd, H2 2019
Uveitis - Pipeline by RiniSight Inc, H2 2019
Uveitis - Pipeline by Santen Pharmaceutical Co Ltd, H2 2019
Uveitis - Pipeline by SFA Therapeutics LLC, H2 2019
Uveitis - Pipeline by Siam Bioscience Co Ltd, H2 2019
Uveitis - Pipeline by Tarsius Pharma Ltd, H2 2019
Uveitis - Pipeline by Tianjin Pharmaceuticals Group Co Ltd, H2 2019
Uveitis - Dormant Projects, H2 2019
Uveitis - Discontinued Products, H2 2019

List of Figures
Number of Products under Development for Uveitis, H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products by Top 10 Targets, H2 2019
Number of Products by Stage and Top 10 Targets, H2 2019
Number of Products by Top 10 Mechanism of Actions, H2 2019
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019
Number of Products by Top 10 Routes of Administration, H2 2019
Number of Products by Stage and Top 10 Routes of Administration, H2 2019
Number of Products by Top 10 Molecule Types, H2 2019
Number of Products by Stage and Top 10 Molecule Types, H2 2019
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Aciont Inc
  • Akari Therapeutics Plc
  • Aldeyra Therapeutics Inc
  • Alvotech ehf
  • Apidel SA
  • Apitope International NV
  • Bonac Corp
  • Bristol-Myers Squibb Co
  • Chugai Pharmaceutical Co Ltd
  • Dobecure SL
  • E&B Technologies LLC
  • Elasmogen Ltd
  • Eleusis Ltd
  • Eli Lilly and Co
  • Emerald Bioscience Inc
  • EnhanX Biopharm Inc
  • Enzo Biochem Inc
  • EyePoint Pharmaceuticals Inc
  • Eyevensys SAS
  • EyGen Ltd
  • F. Hoffmann-La Roche Ltd
  • Galapagos NV
  • HanAll Biopharma Co Ltd
  • HanAll Biopharma Co Ltd
  • Idogen AB
  • InSight Biopharmaceuticals Ltd
  • IVERIC bio Inc
  • Kodiak Sciences Inc
  • Kv1.3 Therapeutics
  • MetrioPharm AG
  • Mitotech SA
  • Naegis Pharmaceuticals Inc
  • NeuClone Pty Ltd
  • Novaliq GmbH
  • Novartis AG
  • Oculis SA
  • OKYO Pharma Ltd
  • OncoNOx ApS
  • Orchid Pharma Ltd
  • OSE Immunotherapeutics
  • Palatin Technologies Inc
  • Panag Pharma Inc
  • Panoptes Pharma GesmbH
  • Pfizer Inc
  • Pharmapraxis
  • Re-Pharm Ltd
  • RiniSight Inc
  • Santen Pharmaceutical Co Ltd
  • SFA Therapeutics LLC
  • Siam Bioscience Co Ltd
  • Tarsius Pharma Ltd
  • Tianjin Pharmaceuticals Group Co Ltd
Note: Product cover images may vary from those shown
Adroll
adroll